Clinical Trials
20 trialsNCT02220985 2026-06-01
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT03959241 2024-04-04
1703/1801
Medical College of Wisconsin
Phase 3 Completed
NCT01858740 2024-03-12
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00003838 2023-09-21
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01951885 2023-09-11
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center
Phase 3 Completed
NCT01572662 2023-06-29
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00406393 2023-01-04
BMT CTN 0402
Medical College of Wisconsin
Phase 3 Completed
NCT02129582 2021-05-07
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01338987 2021-03-18
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00741455 2020-11-23
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT02487069 2020-03-05
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
Nanfang Hospital, Southern Medical University
Phase NA Completed
NCT02208037 2019-01-23
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT01789255 2018-07-24
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002766 2016-02-22
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT01390402 2016-02-03
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00402558 2015-05-08
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01188798 2013-03-21
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00787761 2012-10-01
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Northside Hospital, Inc.
Phase 2 Completed
NCT00027924 2010-04-02
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00002789 2010-03-30
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 3 Completed